ReviewFrontiers in microbiology2016
Antimicrobial Drugs in Fighting against Antimicrobial Resistance.
Review in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Reprogrammed SimCells for antimicrobial therapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- RND efflux pump inhibitor-like natural products as antibiotic adjuvants against multidrug-resistant gram-negative bacteria: a graded-evidence review.Frontiers in microbiology · 2026Review
- Unveiling the Therapeutic Spectrum of Annona reticulata Linn.: Antibacterial, Insecticidal, and Antidiarrheal Insights.TheScientificWorldJournal · 2026Article
- A probiotic Brevibacillus laterosporus promotes chicken growth performance immunity and gut health.Scientific reports · 2025Article
- Analysis of Antimicrobial Residues and Resistance Profiles ofVeterinary sciences · 2025Article
- Article
- In vitro evaluation of silver-zinc oxide-eugenol nanocomposite for enhanced antimicrobial and wound healing applications in diabetic conditions.Discover nano · 2025Article
- Article
- Auxin-mediated biosynthesis of silver nanoparticles: comprehensive characterisation and antibacterial activity analysis.Frontiers in cellular and infection microbiology · 2025Article
- An Overview of Naphthylimide as Specific Scaffold for New Drug Discovery.Molecules (Basel, Switzerland) · 2024Review
- Unraveling bacterial stress responses: implications for next-generation antimicrobial solutions.World journal of microbiology & biotechnology · 2024Article
- Antibiotic Alternatives: Multifunctional Ultra-Small Metal Nanoclusters for Bacterial Infectious Therapy Application.Molecules (Basel, Switzerland) · 2024Review
- Exploration of novel cationic amino acid-enriched short peptides: design, SPPS, biological evaluation andRSC advances · 2024Article
- Synthesis, Characterisation, and In Vitro Evaluation of Biocompatibility, Antibacterial and Antitumor Activity of Imidazolium Ionic Liquids.Pharmaceutics · 2024Article
- Article
- Characteristics ofPathogens (Basel, Switzerland) · 2022Article
- Antibacterial Properties of Crotoxin fromMolecules (Basel, Switzerland) · 2022Article
- Overview on Strategies and Assays for Antibiotic Discovery.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Green Route Synthesis and Characterization Techniques of Silver Nanoparticles and Their Biological Adeptness.ACS omega · 2022Review
- BDDE-Inspired Chalcone Derivatives to Fight Bacterial and Fungal Infections.Marine drugs · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outbreak of antimicrobial resistance, together with the lack of newly developed antimicrobial drugs, represents an alarming signal for both human and animal healthcare worldwide. Selection of rational dosage regimens for traditional antimicrobial drugs based on pharmacokinetic/pharmacodynamic principles as well as development of novel antimicrobials targeting new bacterial targets or resistance mechanisms are key approaches in tackling AMR. In addition to the cellular level resistance (i.e., mutation and horizontal gene transfer of resistance determinants), the community level resistance (i.e., bilofilms and persisters) is also an issue causing antimicrobial therapy difficulties. Therefore, anti-resistance and antibiofilm strategies have currently become research hotspot to combat antimicrobial resistance. Although metallic nanoparticles can both kill bacteria and inhibit biofilm formation, the toxicity is still a big challenge for their clinical applications. In conclusion, rational use of the existing antimicrobials and combinational use of new strategies fighting against antimicrobial resistance are powerful warranties to preserve potent antimicrobial drugs for both humans and animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.